Journal of advanced research · 2026
A biparatopic antibody targeting the Cε2 and Cε3 domains of IgE disrupts IgE-FcεRI interaction.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhu Lixia, Zheng Peiyi, Cheng Qingyu, Gao Yongshan, Fan Xiaojiao, Huang Xiaoxue, Yao Chengbing, Shang Yuhua, Li Bofeng, Jin Tengchuan
Аннотация
INTRODUCTION: Therapeutic anti-IgE antibodies that block the interaction between immunoglobulin E (IgE) and its high-affinity receptor (FcεRI) have been a popular direction for the treatment of allergic diseases.
OBJECTIVES: Although both the Cε2 and Cε3 domains of IgE play important roles in stabilizing the IgE:FcεRI complex, most of those anti-IgE antibodies target only the Cε3 domain of IgE. Here, we develop a biparatopic antibody (SA25-A4-IgG1Fc) targeting both the Cε2 and Cε3 domains of IgE, which disrupts IgE-FcεRI interaction.
METHODS: We link nanobody A4 and SA25 by a (GGGGS)4 linker, and fuse with a human IgG1Fc tag to generate SA25-A4-IgG1Fc. The FcεRI disruption effect of SA25-A4-IgG1Fc is tested by enzyme-linked immunosorbent assay, flow cytometry, surface plasmon resonance, and food allergic humanized mice.
RESULTS: We identify an alpaca nanobody A4, which recognizes the Cε2 domain of IgE with nanomolar affinity, and a shark nanobody SA25, which binds the Cε3 domain of IgE competitively with FcεRⅠ. Targeting both the Cε2 and Cε3 domains of IgE, the biparatopic antibody (SA25-A4-IgG1Fc) binds to IgE with picomolar affinity, and blocks IgE-FcεRI interaction with greater potency than omalizumab in vitro. In addition, SA25-A4-IgG1Fc also removes IgE from human basophils and mast cells with high efficacy, and inhibits ovalbumin (OVA)-induced IgE-dependent food allergy in IgE/FcεRⅠ humanized mice in vivo.
CONCLUSION: Our results demonstrate that the biparatopic antibody SA25-A4-IgG1Fc is a promising inhibitor for the treatment of food allergy, and provide a novel idea for the development of anti-IgE antibodies.
OBJECTIVES: Although both the Cε2 and Cε3 domains of IgE play important roles in stabilizing the IgE:FcεRI complex, most of those anti-IgE antibodies target only the Cε3 domain of IgE. Here, we develop a biparatopic antibody (SA25-A4-IgG1Fc) targeting both the Cε2 and Cε3 domains of IgE, which disrupts IgE-FcεRI interaction.
METHODS: We link nanobody A4 and SA25 by a (GGGGS)4 linker, and fuse with a human IgG1Fc tag to generate SA25-A4-IgG1Fc. The FcεRI disruption effect of SA25-A4-IgG1Fc is tested by enzyme-linked immunosorbent assay, flow cytometry, surface plasmon resonance, and food allergic humanized mice.
RESULTS: We identify an alpaca nanobody A4, which recognizes the Cε2 domain of IgE with nanomolar affinity, and a shark nanobody SA25, which binds the Cε3 domain of IgE competitively with FcεRⅠ. Targeting both the Cε2 and Cε3 domains of IgE, the biparatopic antibody (SA25-A4-IgG1Fc) binds to IgE with picomolar affinity, and blocks IgE-FcεRI interaction with greater potency than omalizumab in vitro. In addition, SA25-A4-IgG1Fc also removes IgE from human basophils and mast cells with high efficacy, and inhibits ovalbumin (OVA)-induced IgE-dependent food allergy in IgE/FcεRⅠ humanized mice in vivo.
CONCLUSION: Our results demonstrate that the biparatopic antibody SA25-A4-IgG1Fc is a promising inhibitor for the treatment of food allergy, and provide a novel idea for the development of anti-IgE antibodies.